Xilio Therapeutics, Inc.
A biotechnology company in Waltham, Massachusetts, that designs cancer treatments meant to switch on only inside a tumor, so the body's own immune system attacks the cancer while healthy tissue is left alone. Its pipeline includes tumor-activated proteins like an IL-12 therapy, built on a masking platform the company calls GPS. Founded in 2016 as Akrevia Therapeutics and renamed Xilio in 2020, the name comes from the Latin phrase "ex nihilo," meaning "out of nothing," nodding to the idea of creating a new kind of cancer medicine.
Bought 2.25M
Sold 5.2K
Granted 44.3K · Bought 36.3K
Granted 33.3K
Granted 38.8K · Sold 14.0K
Bought 75.0K
Granted 10.0K · Sold 3.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Gilead Sciences, Inc.10% owner · 2 transactions | — | 9.11Mas of Dec 2024 | — | 2.25M | — |
| Atlas Venture Associates Opportunity I, L.P. +5 co-filers10% owner · 6 transactions | — | 5.51Mas of Feb 2024 | — | — | 5.2K |
| Russo RenePRESIDENT AND CEO, Director · 2 transactions | +62.2% | 325.4K | 44.3K | 36.3K | — |
| Luptakova KatarinaCHIEF MEDICAL OFFICER · 2 transactions | — | 33.3K | 33.3K | — | — |
| Frankenfield Christopher JamesChief Financial Officer · 4 transactions | — | 24.8K | 38.8K | — | 14.0K |
| Shannon James SamuelDirector · 3 transactions | — | 10.0K | — | 75.0K | — |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING · 4 transactions | — | 6.4K | 10.0K | — | 3.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +2.33M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.